Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Tela Bio Q3 2026 Results: Net Loss of $9.3M, Loss Widens

TELA Bio reported a net loss of $32.8 million for the nine months ended September 30, 2026, as revenue declined slightly to $57.3 million from $59.4 million in the prior year. A significant balance sheet shift occurred as $56.3 million in debt was reclassified to current liabilities, contributing to a total stockholders' deficit of $24.6 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue19.020.7
Gross profit12.314.0
Profit before tax-9.2-8.6
Net income-9.3-8.6
EPS (diluted, $ a share)$-0.16$-0.19

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-8.4%
Gross margin64.9%
Operating margin-38.5%
Source

10-Q filed with the SEC, NASDAQ: TELA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Tela Bio, Inc.: key numbers

Share price
$0.7616Close, Nov 16
Market cap
$34.4M
Shares outstanding
45.19MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Tela Bio, Inc.

All →
4:05 PM ET 8-K
Financial Results

Tela Bio Financial Results

TELA Bio reported Q3 2026 revenue of $19.0 million, an 8% decrease year-over-year primarily due to lower OviTex PRS volumes. The company implemented a strategic cost reduction initiative to reduce annual operating expenses by $17.0 million and extend its cash runway into 2028. During the quarter, the company also regained Nasdaq compliance and received 510(k) clearance for its Liora Monofilament Scaffold.

Term
Q3 2026

“My first quarter as CEO was focused on putting a plan in place to return TELA Bio to growth. I joined because I believe OviTex is best-in-class technology and that we are well positioned to win in an evolving soft tissue repair and reconstruction market.”

Heather Getz, Chief Executive Officer of TELA Bio

“Our cost reduction initiative allows us to thoughtfully reallocate resources, supports a return to topline growth, and extends our cash runway. In the third quarter alone, we reduced our adjusted EBITDA loss by 55% versus the second quarter of 2026 while delivering sequential revenue growth in the US hernia market and continued year-over-year growth in Europe.”

Heather Getz, Chief Executive Officer of TELA Bio
4:05 PM ET 8-K
Shareholder Meeting

Tela Bio Shareholder Meeting

TELA Bio held a Special Meeting of Stockholders on October 8, 2026, where shareholders approved an amendment to the Certificate of Incorporation to authorize a reverse stock split at a ratio between 1-for-5 and 1-for-15. However, the company noted it does not intend to effect the split at this time as it recently regained compliance with Nasdaq's minimum bid price requirement.

4:06 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Tela Bio Nasdaq/NYSE Compliance Notice

TELA Bio, Inc. received a formal notification from Nasdaq stating that the company has regained compliance with the minimum bid price requirement for continued listing. The matter is now closed, and the company's common stock will continue to trade on the Nasdaq Global Market under the symbol 'TELA'.

Counterparty
The Nasdaq Stock Market LLC
8:05 AM ET 8-K
Regulatory Approval

Tela Bio Regulatory Approval

TELA Bio received FDA 510(k) clearance for its Liora Monofilament Scaffold, a fully resorbable surgical mesh for soft tissue reinforcement. This marks a significant milestone as it is the first fully resorbable synthetic product in the company's portfolio to be designed and produced in-house.

“FDA 510(k) clearance is a significant milestone for TELA Bio as Liora is the first fully resorbable synthetic product in our portfolio to be designed and produced in-house by our team of innovative engineers.”

Heather Getz, CEO of TELA Bio
4:05 PM ET 8-K
Loan & Debt

Tela Bio Debt Financing Update with Perceptive Credit Holdings V, LP

TELA Bio entered into a Limited Consent to its existing Credit Agreement with Perceptive Credit Holdings V, LP. The agreement waives the testing of the minimum revenue covenant for the fiscal quarters ending September 30, 2026, and December 31, 2026, providing the company with temporary financial flexibility.

Counterparty
Perceptive Credit Holdings V, LP
4:31 PM ET Form 4
Insider Buying

Tela Bio Director Joseph H. Capper Buys $88.8K of Stock

Joseph H. Capper, Director, bought 75,000 shares of Tela Bio, Inc. at $1.17 to $1.22 a share (average $1.18) in 2 transactions, worth $88.8K in total between Sep 16, 2026 and Sep 17, 2026. Shares held after the trade: 179,827 (+16.1%).

Value
$88.8K
Shares
75,000
Average price
$1.18
Role
Director
Holding change
+16.1%
Trade date
Sep 16, 2026 to Sep 17, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.